curasan AG

euro adhoc: Capital measures
Curasan AG acquires rights to REVOIS® implant system

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@


Ad hoc announcement pursuant to Section 15 WpHG

Kleinostheim, December 15, 2006 - curasan AG (ISIN: DE 000 549 453 8), a company listed in the Prime Standard, has concluded an agreement with the licensor of the REVOIS® implant system it distributes, whereby the right of pre- emption concerning the purchase of all legal rights associated with the aforementioned product shall be executed with immediate effect. This decision was prompted by the favourable response shown by both national and international experts within the field.

Part of the purchase consideration is to be settled in the form of 500,000 new no-par-value shares, which shall be authorised for trading and are to be issued from Authorised Capital I (Genehmigtes Kapital I). Furthermore, additional purchase price components have been agreed; they are to be financed via the future revenues generated from the distribution of REVOIS®. Both parties have agreed not to disclose details of the overall purchase price, which is dependent on the product's sales performance.

Thus, curasan AG holds all rights for the manufacture and global marketing of the REVOIS® implant system, including the rights associated with trademarks and patent filings. In taking this step, the company has ensured that investments in market development will have a sustained positive effective on future corporate performance.

About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a leading innovator within the growth market of bone and tissue regeneration. The company has developed a comprehensive product range centred around its synthetic bone regeneration material Cerasorb®, for use in soft and hard tissue. With the REVOIS implant system, the company's sales is focusing more prominently  on the growth market of dental surgery/implantology. The majority of new products emerging from the substantial development pipeline are to be offered under licence within other medical fields. For further information, please visit curasan's corporate website at:


                                                 Ad hoc announcement


@@start.t2@@end of announcement                                                 euro adhoc 15.12.2006 08:19:45

ots Originaltext: curasan AG
Im Internet recherchierbar:

Further inquiry note:
Dr. Erwin Amashaufer, curasan AG, Tel. (0) 6027/46 86-465, email:
Andrea Weidner, curasan AG, Tel. (0) 6027/ 46 86-467, E-Mail:

Branche: Biotechnology
ISIN:      DE0005494538
WKN:        549453
Index:    CDAX, Classic All Share, Prime All Share
Börsen:  Frankfurter Wertpapierbörse / regulated dealing/prime
              Börse Berlin-Bremen / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Niedersächsische Börse zu Hannover / free trade
              Bayerische Börse / free trade

Weitere Meldungen: curasan AG

Das könnte Sie auch interessieren: